Ralf Gutzmer
Johannes Wesling Klinikum Minden · Universitätsklinik für Dermatologie, Venerologie, Allergologie und Phlebologie Johannes Wesling Klinikum Minden Mühlenkreiskliniken Universitätsklinikum der Ruhr-Universität Bochum
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Ralf Gutzmer as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:00 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07387198 · Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor CemiplimabInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Merkel Cell Carcinoma, Stage I, Merkel Cell Carcinoma, Stage II, Neoadjuvant Immunotherapy · principal investigator
- Ph2NCT06981325 · Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) PatientsInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest · recruiting · Basal Cell Carcinoma (BCC), First Line Treatment · principal investigator
- N/ANCT04066504 · Post-authorization Safety Study on the Long Term Safety of Sonidegib in Patients With Locally Advanced Cell CarcinomaSun Pharmaceutical Industries Limited · completed · Basal Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:00 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:00 UTC. The ranking covers the 200 most relevant of 75 PubMed records, and a shared surname and initials can bring in a namesake. All 75 on PubMed
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial.Lancet · 20122,428 citationsRCR 64.2
- 2,199 citationsRCR 66.5
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.N Engl J Med · 20181,569 citationsRCR 53.2
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol · 2018820 citationsRCR 27.7
- 542 citationsRCR 20.2
- 450 citationsRCR 14.4
- 430 citationsRCR 13.0
- Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial.Lancet Oncol · 2017410 citationsRCR 12.3
- Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol · 2017396 citationsRCR 12.9
- 374 citationsRCR 14.3